{
    "id": "dbpedia_8098_0",
    "rank": 81,
    "data": {
        "url": "https://adisinsight.springer.com/drugs/800073546",
        "read_more_link": "",
        "language": "en",
        "title": "Simcere Pharmaceutical Group",
        "top_image": "https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/ajax_loader.gif",
        "meta_img": "",
        "images": [
            "https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/ajax_loader.gif",
            "https://adisinsight.springer.com/assets/images/adisinsight_logo.svg",
            "https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/loading_search.gif",
            "https://adisinsight.springer.com/assets/images/icons/springer.svg",
            "https://adisinsight.springer.com/assets/images/icons/springernature.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "SP 002 - Simcere Pharmaceutical Group",
            "SP002 Simcere Pharmaceutical group",
            "SP002 Simcere pharmaceutical group",
            "Ubiquitin-specific protease inhibitors",
            "Antineoplastics",
            "Simcere Zaiming"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "SP 002 is a selective USP1 (ubiquitin-specific peptidase 1) inhibitor being developed by Simcere Zaiming (a subsidiary of Simcere Pharmaceuticals Group) for the",
        "meta_lang": "en",
        "meta_favicon": "https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "http://adisinsight.springer.com",
        "text": "With your consent we’ll provide this information to your organization’s account administrator to aid in the renewal decision and we will send you important updates about AdisInsight.\n\nPlease refer to our privacy policy for information on how we protect your personal information.\n\nDo you need help? Please contact one of our AdisInsight experts. We aim to get back to you with personalized answer within 24 hours."
    }
}